CollPlant(CLGN) - 2025 Q4 - Annual Report

Financial Performance - The company incurred a total comprehensive loss of $11.5 million for the year ended December 31, 2025, and a total comprehensive loss of $16.6 million for the year ended December 31, 2024, with an accumulated deficit of $124.8 million as of December 31, 2025[55]. - The company anticipates continuing to incur significant expenses and operating losses in the foreseeable future, with expenses expected to increase substantially due to ongoing research and development activities[57]. - Management has expressed substantial doubt about the company's ability to continue as a going concern, which may hinder its ability to obtain new financing on reasonable terms[65]. - The company has relied on revenues from product sales, licensing, and milestone payments for financing, but future revenues will depend on market acceptance and regulatory approvals[56]. Cash and Funding - As of December 31, 2025, the company's cash and cash equivalents were $5.6 million, and it has received payments under the AbbVie Development Agreement totaling $26 million in the past[60]. - The company plans to continue advancing its product candidates through preclinical and clinical development, which will require additional funding that may not be available on acceptable terms[59]. - The company has implemented a cost-cutting and workforce reduction plan to manage its financial position[60]. Product Development and Commercialization Risks - The company faces risks related to the commercialization of its products, including limited clinical data and competition from more advanced therapies[46]. - The commercial success of products will depend on market acceptance by physicians, patients, and third-party payors, which is uncertain[71]. - Limited clinical data for products may hinder acceptance by the medical community, affecting sales potential[75]. - Manufacturing capabilities for rhCollagen need improvement to meet market demand, requiring significant investment[76]. - The company has limited experience in selling and marketing its products, which may impact revenue generation[83]. - The availability of reimbursement from payors is essential for product commercialization, and lack of it could limit market success[89]. - The company operates in a competitive environment with rapid technological changes, posing risks to product commercialization[85]. Regulatory Compliance and Challenges - Regulatory compliance is critical, as failure could lead to sanctions or revocation of product approvals[80]. - The regulatory approval process for the company's novel products may be more expensive and time-consuming compared to traditional products, potentially impacting timelines[95]. - The company must navigate a complex regulatory environment, increasing the risk of potential violations[112]. - The company is subject to stringent regulations by the FDA and European regulatory authorities, which could impose penalties or restrictions if compliance is not met[118]. - The FDA has increased scrutiny of the medical device industry, which may lead to enforcement actions that could restrict manufacturing and marketing capabilities[123]. Intellectual Property and Legal Risks - The company has an extensive patent portfolio, but maintaining it is costly and non-compliance could lead to loss of patent rights, affecting competitive position[184]. - The strength of the company's intellectual property rights is uncertain, and failure to protect these rights could impair its ability to commercialize products[186]. - The company may face litigation related to intellectual property, which could be expensive and time-consuming, potentially affecting its financial resources[196]. - Third-party claims of intellectual property infringement could delay product development and commercialization efforts, leading to significant financial implications[191]. Market and Economic Conditions - Economic conditions, including inflation and geopolitical events, may negatively impact the company's operating results and growth rates, leading to delayed sales cycles and increased price competition[177]. - The company faces potential product liability claims that could result in substantial costs and negatively impact its business reputation and ability to commercialize products[166]. - Future healthcare reforms may impact reimbursement rates, affecting demand for the company's products and overall financial performance[130]. Corporate Governance and Compliance - The company is a foreign private issuer and is subject to reduced reporting requirements, which may affect the attractiveness of its ordinary shares to investors[226]. - The company may need to improve its accounting systems and controls to comply with SEC reporting requirements, which could incur significant costs[220]. - The company’s reliance on home country corporate governance practices may provide less protection to shareholders compared to U.S. domestic issuers[235]. - A loss of foreign private issuer status would result in significantly higher regulatory and compliance costs under U.S. securities laws[237].